GAS6 and neoplasm: Clinically, GAS6 expression in tumor specimens has been shown to be an adverse prognostic factor in urothelial, ovarian, lung adenocarcinoma, gastric cancer, and glioblastoma (Table 2, [14,23,31,35,36,37,38]).